WinSanTor
Private Company
Funding information not available
Overview
WinSanTor is pioneering a potentially first-in-class, nerve-regenerating topical treatment for peripheral neuropathies, a large and underserved market. Its lead candidate, WST-057, has generated promising Phase 2a data published in eBioMedicine (The Lancet) and is now in Phase 3 development. The company is privately held and has been primarily funded by over $40 million in non-dilutive grants from U.S. and Canadian government agencies. With a leadership team and founding KOLs possessing deep expertise in neuropathy, WinSanTor aims to deliver the first disease-modifying therapy for millions of patients.
Technology Platform
Proprietary in vitro drug screening assay using primary sensory neurons to identify compounds that promote neurite outgrowth and nerve regeneration, leading to the development of topical disease-modifying therapies.
Opportunities
Risk Factors
Competitive Landscape
The current competitive landscape for peripheral neuropathy is dominated by generic pain management drugs (e.g., gabapentin, duloxetine) that only treat symptoms. WinSanTor's potential direct competitors are other companies developing disease-modifying or regenerative therapies, which are mostly in earlier preclinical or clinical stages, giving WST-057 a possible first-mover advantage if successful.